The European Patent Office (EPO) has published patent application EP4626878A1, filed by Neumora Therapeutics, Inc., concerning novel methods for treating neurological disorders. The publication includes details on chemical classifications (C07D 401/04) and therapeutic applications (A61P 25/02, A61P 25/28), along with specific drug compounds (A61K 31/513).

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it signifies ongoing innovation and potential future market exclusivity for treatments in the neurological disorder space. Companies operating in this sector should be aware of this filing as part of their competitive intelligence and intellectual property landscape monitoring.